25 July 2024
Latham & Watkins Advises on Kestra Medical Technologies’ US$196 Million Financing Round
Advising firms
Deal team
6 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Robbie McLaren Lead | Latham & Watkins LLP | Partner | corporate | London |
| Matthew O'Connor | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Kirill Grishin | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Emily Taylor | Latham & Watkins LLP | Partner | US corporate | Boston |
| Xavier Renard | Latham & Watkins LLP | Partner | French tax | Paris |
| Hugo Matricon | Latham & Watkins LLP | Associate | Not stated | Not stated |
3 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 196m (US$196 million)
- What the figure measures
- Total transaction value
- Client
- Not stated
- Counterparties
- Kestra Medical Technologies (Issuer)
Andera Partners (Investor)
Ally Bridge Group (Investor)
Longitude Capital (Investor)
Omega Funds (Investor)
Gilmartin Capital (Investor)
T. Rowe Price Investment Management, Inc. (Investor)
Eventide Asset Management (Investor)
Bain Capital (Investor)
Endeavour Vision (Investor)